CYCLOPHARM LIMITED — Capital/Financing Update 2012

Aug 23, 2012

==> picture [151 x 48] intentionally omitted <==

24 August 2012 The Manager Company Announcements Office Australian Securities Exchange Limited 20 Bridge Street Sydney NSW 2000

cyclo medica molecular imaging techne gas Cyclopharm Ltd ABN 74 116 931 250 Bldg 75 Business & Technology Park New Illawarra Road Lucas Heights NSW 2234 Australia POB 350 Menai Central NSW 2234 T 61 2 9541 0411 F 61 2 9543 0960 www.cyclopharm.com.au

Cyclopharm to Establish Operations in Queensland

The Directors of Cyclopharm Limited (ASX: CYC) are pleased to announce that the company has entered into a tripartite agreement with Queensland’s Mater Misericordiae Health Services group (MMHS) and Queensland X-Ray a wholly owned subsidiary of Sonic Healthcare Limited (Sonic).

The agreement will see the establishment of a cyclotron manufacturing facility at the Mater Hospital located in South Brisbane. The facility will produce pharmaceuticals used in Positron Emission Tomography (PET).

Under the terms of the agreement:

• Cyclopharm will establish a state of the art cyclotron manufacturing facility on the grounds of the South Brisbane Mater Hospital by 2014.

• Cyclopharm will supply Queensland X-Ray’s Queensland facilities with flurodeoxyglucose (FDG), the primary diagnostic pharmaceutical used in PET, for a minimum period of 5 years

• Until the Brisbane facility is operational Cyclopharm will continue to supply Queenland X-Ray’s FDG requirements from its existing Cyclotron facility in Sydney

This is an outstanding advancement for Cyclopharm as it delivers an underwritten entry into the high growth Queensland FDG market, supplying Queensland’s largest radiology group at Queensland largest medical precinct.

This is an important step in our strategy to become Australia’s leading provider of FDG and emerging PET radiopharmaceutials. The new facility will also provide us with a platform for further growth in the Queensland market.

MMHS in Queensland cares for more than 500,000 patients each year in its seven hospitals. The Health District in which the cyclotron will reside is one of the largest in Australia boasting nearly 1,000 beds.

Over the coming months, Cyclopharm will work with MMHS to finalise the design and scope of the new cyclotron facility. The precise capital cost to Cyclopharm, and related financing method, will not be determined until this design is finalised, the

Page 1 of 2

designated land has been acquired by MMHS and the lease has been approved by the respective boards. However, at this stage, the company expects it will be in the range of approximately $5 million to $7.5 million.

==> picture [172 x 44] intentionally omitted <==

James McBrayer Managing Director, CEO and Company Secretary

Contact details:

Mr James McBrayer Managing Director, CEO and Company Secretary Cyclopharm Limited T: +61 2 9541 0411

Background

Cyclopharm Limited

Cyclopharm is a radiopharmaceutical company servicing the global medical community. The Company’s mission is to provide nuclear medicine and other clinicians with the ability to improve patient care outcomes.

Cyclopharm achieves this objective through the provision of radiopharmaceutical products, Technegas (for lung imaging) and Molecular Imaging / PET radiopharmaceuticals (used in cancer, brain and cardiac imaging). Our customers are nuclear medicine departments located within hospitals and clinics.

Technegas

The Technegas technology is a structured ultra-fine dispersion of radioactive labeled carbon, produced by using dried Technetium-99m in a carbon crucible, micro furnaced for a few seconds at around 2,700[o] C. The resultant gaseous substance is inhaled by the patient (lung ventilation) via a breathing apparatus, which then allows multiple views and tomography imaging under a gamma or single photon emission computed tomography (SPECT) camera for the superior diagnosis of pulmonary emboli (blood clots in the lungs).

Positron Emission Tomography (PET)

PET radiopharmaceuticals target specific tissues / organs, concentrate there, and the attached radioisotope emits radiation, which is then detected by a PET or PET / CT gamma (collectively PET camera). These imaging modalities help physicians improve their ability to detect and determine the location, extent and stage of cancer, neurological disorders and cardiac disease. By improving diagnosis, PET scans aid physicians in selecting better courses of treatment, as well as assessing whether treatment is effective or should be changed.

Page 2 of 2